Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in HSCT-Associated Thrombotic Microangiopathy
2023-510107-22-00Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in transplant-associated thrombotic microangiopathy (TA-TMA) comparing Ravulizumab (Ultomiris) with Placebo (2 arms). Primary endpoint: Event-free survival during the 26-week treatment period. Started Oct 2020; status: completed.
02
Drugs
ravulizumab
03
Conditions
transplant-associated thrombotic microangiopathy (TA-TMA)
Beyond the preview
Go deeper on 2023-510107-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510107-22-00.